Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

W. Timothy Garvey, Juan P. Frías, Ania M. Jastreboff, +90

The Lancet

ObesityMetabolic SyndromeDiabetes ManagementInsulin ManagementDiabetes +4

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

Surya P. Bhatt, Klaus F. Rabe, Nicola A. Hanania, +19

New England Journal of Medicine

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

Tim Harrison, Pascal Chanez, Francesco Menzella, +223

The Lancet Respiratory Medicine

AsthmaSevere Eosinophilic AsthmaAllergyInflammatory Lung DiseaseAllergy Medicine +8

Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study

Andrew Menzies‐Gow, Michael E. Wechsler, Christopher E. Brightling, +184

The Lancet Respiratory Medicine

AsthmaRheumatologyAllergyClinical TrialsUncontrolled Asthma +7

Preemptive Oral Treatment With Sumatriptan During a Cluster Period

I. Monstad, Annette Krabbe, Giuseppe Micieli, +4

Headache The Journal of Head and Face Pain

<scp>CYT</scp>003, a <scp>TLR</scp>9 agonist, in persistent allergic asthma – a randomized placebo‐controlled Phase 2b study

Thomas B. Casale, Jeremy Cole, Ekkehard Beck, +7

Allergy

Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial

Dave Singh, Christopher E. Brightling, Klaus F. Rabe, +108

The Lancet Respiratory Medicine

Advanced Lung DiseaseClinical TrialsTezepelumab Versus PlaceboPulmonary MedicinePharmacotherapy +2

Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial

Pamela L. Zeitlin, Mila A. Leong, Jeremy Cole, +4

Journal of Asthma and Allergy

Inhaled fluticasone furoate/vilanterol does not affect hypothalamic‐pituitary‐adrenal axis function in adolescent and adult asthma: randomised, double‐blind, placebo‐controlled study

Ann Allen, Isabelle Schenkenberger, Roopa Trivedi, +4

The Clinical Respiratory Journal

Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study

Alessandro Fiocchi, Wanda Phipatanakul, Robert S. Zeiger, +11

European Respiratory Journal